Merck raised its revenue outlook as sales of new drugs increased, but lowered its profit guidance because of charges related to its acquisition of Terns Pharmaceuticals.
Impact: The stock may see mixed reactions, with revenue growth supporting the price while the profit cut could weigh on it.
Not investment advice